Cost-Effectiveness Analysis of Gemtuzumab Ozogamicin for First-Line Treatment of Patients with Cd-33 Positive Acute Myeloid Leukaemia in Spain
ClinicoEconomics and Outcomes Research（2021）
Key words
cost-effectiveness,gemtuzumab ozogamicin,acute myeloid leukaemia,Spain
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined